Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
British Journal of Cancer,
Dewdney A et al. – Bevacizumab–induced hypertension did not predict radiological response or survival in the study. The results highlight a number of important issues regarding the use of hypertension as a biomarker.